ABK Biomedical Breaks Ground on Missouri Cancer Device Plant
Image
Ashland, Missouri – October 02, 2026 -- ABK Biomedical Inc. has launched construction of a commercial-scale manufacturing facility at Cartwright Business Park in Ashland, Missouri, designed to produce its Eye90 microspheres for liver cancer treatment. The groundbreaking, attended by Missouri Governor Mike Kehoe, follows the company's April announcement selecting Ashland for its long-term U.S. manufacturing base.
Facility targets commercial-scale output of yttrium-90 radioembolization device
The planned Good Manufacturing Practice (GMP) facility will be built for commercial-scale production of Eye90 microspheres, a clinical-stage yttrium-90 radioembolization device still under development for liver cancer treatment. The devices remain investigational and are not approved for use outside authorized clinical trials.